Sökning: "Interleukin-2 analysis"
Visar resultat 1 - 5 av 8 avhandlingar innehållade orden Interleukin-2 analysis.
1. Human intestinal T lymphocytes : a comparative analysis of phenotype and function in normal and inflamed mucosa
Sammanfattning : The epithelial lining of the gut must allow immediate contact with beneficial components as nutrients and normal microflora. At the same time it runs the constant risk of attack from pathogenic microbes and noxious agents. LÄS MER
2. Affibody molecules for proteomic and therapeutic applications
Sammanfattning : This thesis describes generation and characterization of Affibody molecules with future applications in proteomics research, protein structure determinations, therapeutic treatment of disease and medical imaging for in vivo diagnostics. Affibody molecules are engineered affinity proteins developed by combinatorial protein engineering from the 58-residue protein A-derived Z domain scaffold. LÄS MER
3. Inhibition of acute allogaft rejection - experimental transplant studies with biological and chemical immunosuppressants
Sammanfattning : In clinical transplantation immunosuppressive agents are used in combination with the objective to achieve additive effects and less toxicity. A large number of novel drugs are candidates for clinical introduction at this time and experiments in animal models have an important role to play. LÄS MER
4. Factors predicting progression of chronic kidney disease in IgA nephropathy
Sammanfattning : Glomerulonephritis (GN) is the main cause of chronic kidney disease (CKD) in patients on renal replacement therapy, with IgA nephropathy (IgAN) being the most frequent single diagnosis. Patients with reduced kidney function and/or proteinuria have an increased risk of premature cardiovascular disease (CVD). LÄS MER
5. Leukaemic relapse after allogeneic haematopoietic stem cell transplantation and the use of the graft-versus-leukaemia effect
Sammanfattning : Survival after allogeneic haematopoietic stem cell transplantation (HSCT) has improved over the last decades due to improvements in immunosuppressive regimens and supportive care. Today the major risk of treatment failure is recurrent leukaemia, a risk which has stayed relatively constant over the years. LÄS MER